AIG
TSHA icon

American International Group’s Taysha Gene Therapies TSHA Stock Holding History

American International Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,244
Closed -$73K – 3265
2022
Q1 		$73K Sell
11,244
-791
-7% -$5.91K ﹤0.01% 2716
2021
Q4 		$140K Sell
12,035
-149
-1% -$2.25K ﹤0.01% 2565
2021
Q3 		$227K Sell
12,184
-290
-2% -$5.51K ﹤0.01% 2360
2021
Q2 		$264 Buy
12,474
+7,415
+147% +$171K ﹤0.01% 2332
2021
Q1 		$103 Buy
5,059
+14
+0.3% +$379 ﹤0.01% 2704
2020
Q4 		$134 Buy
+5,045
New +$109K ﹤0.01% 2500

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

American International Group's TSHA Position: Q2 2022 in Review

American International Group sold out of Taysha Gene Therapies (TSHA) in Q2 2022, closing a stake of 11,244 shares — an estimated $73K sold.

American International Group first reported a position in TSHA in Q4 2020 and held it in 6 quarters. The position peaked at $227K in Q3 2021. 59 funds tracked by Wall St. Rank hold TSHA as of Q2 2022.

  • American International Group reported no remaining Taysha Gene Therapies position as of Q2 2022 after selling out during the quarter.
  • American International Group sold 11,244 Taysha Gene Therapies shares in Q2 2022, an estimated $73K.
  • American International Group first reported a position in Taysha Gene Therapies in Q4 2020 and held it in 6 quarters.
  • American International Group's Taysha Gene Therapies position peaked at $227K in Q3 2021.
  • 59 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2022.

Based on American International Group's 13F filing for Q2 2022, filed 12 Aug 2022.